Fresenius Kabi Launches Vasopressin Injection, USP Expanding U.S. Critical Care Portfolio

High-Volume Medication is Formulated, Filled and Packaged in the U.S.

LAKE ZURICH, Ill., June 14, 2023 – Fresenius Kabi announced today the availability in the United States of Vasopressin Injection, USP, a generic equivalent to Vasostrict^®. Fresenius Kabi Vasopressin Injection, USP is an approved treatment option for adults with vasodilatory shock and is available in a 20 Units per 1 mL Single Dose Vial.

“Fresenius Kabi is pleased to offer Vasopressin for our U.S. customers further demonstrating our continued commitment to providing high-quality, cost-saving treatment options to clinicians and the patients they serve,” said John Ducker, president and CEO of Fresenius Kabi USA.

Fresenius Kabi produces Vasopressin Injection, USP in the United States where the company has invested nearly $1 billion on an advanced manufacturing and distribution network dedicated to serving U.S. hospitals and health systems. To learn more about how Fresenius Kabi is strengthening America’s supply chain of care, please visit “More in America.”

Please see Important Safety Information below.

INDICATIONS AND USAGE
Vasopressin injection is indicated to increase blood pressure in adults with vasodilatory shock who remain hypotensive despite fluids and catecholamines.

IMPORTANT SAFETY INFORMATION
Vasopressin injection single dose vial is contraindicated in patients with a known allergy or hypersensitivity to 8-L-arginine vasopressin.

Vasopressin injection can worsen cardiac function by decreasing cardiac index.

Patients may experience reversible diabetes insipidus after cessation of treatment with vasopressin. Monitor serum electrolytes, fluid status and urine output after vasopressin discontinuation.

The most common adverse reactions include decreased cardiac output, bradycardia, tachyarrhythmias, hyponatremia and ischemia (coronary, mesenteric, skin, digital).

To report SUSPECTED ADVERSE REACTIONS, contact Fresenius Kabi USA, LLC at 1-800-551-7176, option 5, or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Drug Interactions:

Pressor effects of catecholamines and Vasopressin injection are expected to be additive.

Indomethacin may prolong effects of Vasopressin injection.

Co-administration of ganglionic blockers or drugs causing SIADH may increase the pressor response.

Co-administration of drugs causing diabetes insipidus may decrease the pressor response.

Use in Specific Populations:

Pregnancy: May induce uterine contractions.

Pediatric Use: Safety and effectiveness have not been established.

Geriatric Use: No safety issues have been identified in older patients.

This Important Safety Information does not include all the information needed to use Vasopressin Injection, USP safely and effectively. Please see full prescribing information for Vasopressin Injection, USP at www.fresenius-kabi.com/us.

Vasostrict^® is a registered trademark of Par Pharmaceutical.

About Fresenius Kabi
Fresenius Kabi (www.fresenius-kabi.com/us) is a global health care company that specializes in injectable medicines, biosimilars, and technologies for infusion, transfusion, and clinical nutrition. The company’s products and services are used to help care for critically and chronically ill patients. The company’s U.S. headquarters is in Lake Zurich, Illinois. The company’s global headquarters is in Bad Homburg, Germany. To learn about U.S. career opportunities at Fresenius Kabi, visit us at www.fresenius-kabi.com/us/join-us and follow us on LinkedIn.  

###